原发性肝癌78例血清HCV　RNA和抗HCV的观察

Detection of HCV RNA and anti-HCV in sera from 78 patients with primary liver cancer

用逆转录－聚合酶链反应（ＲＴ－ＰＣＲ）和酶联免疫吸附试验（ＥＬＩＳＡ）检测了７８例原发性肝癌（ＰＬＣ）患者血清丙型肝炎病毒（ＨＣＶ）ＲＮＡ、抗ＨＣＶ和乙型肝炎病毒（ＨＢＶ）免疫学标志物。结果，ＨＣＶＲＮＡ、抗ＨＣＶ和ＨＢｓＡｇ的检出率分别为２，６％（２／７８）、１１．５％（９／７８）和７４．４％（５８／７８）；抗ＨＣＶ在ＨＢｓＡｇ阳性组和ＨＢｓＡｇ阴性组中的检出率分别为３．５％（２／５８）和３５％（７／２０）。提示，在江浙地区，ＨＢＶ感染仍是ＰＬＣ发生的主要危险因素。

Serum samples from 78 patients with primary liver cancer (PLC) were detected for hepatitis C virus (HCV) RNA and antibodies of HCV using reverse transcription-polymerase chain reaction (RT-PCR)and ELISA.The positive rates of HCV RNA,anti-HCV and HBsAg were 2. 6%,11.5% and 74.4%,respectively. The prevalence of anti-HCV was higher in HBsAg negative patients (35 %)than that in HBsAg positive group (3.5 %).The results suggest that HBV infection still plays a key role in the development of PLC in Jiangsu and Zhejiang regions of China.